• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 214

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions

Dr Jason Konner – Psychedelic Oncology and the Future of Cancer Care

The Psychedelic News Feed: November 3 – 9, 2025

The Psychedelic News Feed: November 10 – 16, 2025

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

Psychedelic Research Bulletin: September 2021

Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase...

PTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with...

MindMed Joins Clinical Trials Transformation Initiative

The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex...

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the...

1...213214215...302Page 214 of 302

EDITOR PICKS

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b...

Dr Jason Konner – Psychedelic Oncology and the Future of Cancer...

The Psychedelic News Feed: November 3 – 9, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©